| __timestamp | Agios Pharmaceuticals, Inc. | CymaBay Therapeutics, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 19120000 | 8185000 |
| Thursday, January 1, 2015 | 35992000 | 8871000 |
| Friday, January 1, 2016 | 50714000 | 9645000 |
| Sunday, January 1, 2017 | 71124000 | 12387000 |
| Monday, January 1, 2018 | 114145000 | 14381000 |
| Tuesday, January 1, 2019 | 132034000 | 19238000 |
| Wednesday, January 1, 2020 | 149070000 | 17425000 |
| Friday, January 1, 2021 | 121445000 | 23040000 |
| Saturday, January 1, 2022 | 121673000 | 25116000 |
| Sunday, January 1, 2023 | 119903000 | 51953000 |
| Monday, January 1, 2024 | 156784000 |
In pursuit of knowledge
In the competitive world of biotechnology, managing Selling, General, and Administrative (SG&A) expenses is crucial for financial health. Over the past decade, Agios Pharmaceuticals, Inc. and CymaBay Therapeutics, Inc. have taken different paths in optimizing these costs. From 2014 to 2023, Agios Pharmaceuticals saw a staggering 526% increase in SG&A expenses, peaking in 2020. In contrast, CymaBay Therapeutics maintained a more conservative growth, with a 535% increase, but from a much lower base. By 2023, CymaBay's SG&A expenses were approximately 43% of Agios's, highlighting their more efficient cost management. This data underscores the importance of strategic financial planning in the biotech sector, where every dollar saved can be reinvested into groundbreaking research and development.
Breaking Down SG&A Expenses: Eli Lilly and Company vs Agios Pharmaceuticals, Inc.
Selling, General, and Administrative Costs: Sanofi vs CymaBay Therapeutics, Inc.
BeiGene, Ltd. vs CymaBay Therapeutics, Inc.: SG&A Expense Trends
Who Optimizes SG&A Costs Better? Pharming Group N.V. or Agios Pharmaceuticals, Inc.
Breaking Down SG&A Expenses: Amneal Pharmaceuticals, Inc. vs CymaBay Therapeutics, Inc.
Comparing SG&A Expenses: CymaBay Therapeutics, Inc. vs Xenon Pharmaceuticals Inc. Trends and Insights
Who Optimizes SG&A Costs Better? CymaBay Therapeutics, Inc. or ImmunityBio, Inc.
Cost Management Insights: SG&A Expenses for CymaBay Therapeutics, Inc. and MannKind Corporation
Who Optimizes SG&A Costs Better? CymaBay Therapeutics, Inc. or Evotec SE
Cost Management Insights: SG&A Expenses for Xenon Pharmaceuticals Inc. and Agios Pharmaceuticals, Inc.
Breaking Down SG&A Expenses: Agios Pharmaceuticals, Inc. vs Wave Life Sciences Ltd.
Selling, General, and Administrative Costs: Agios Pharmaceuticals, Inc. vs Amphastar Pharmaceuticals, Inc.